Leukotrienes and kidney diseases.

作者: Menachem Rubinstein , Efrat Dvash

DOI: 10.1097/MNH.0000000000000381

关键词:

摘要: Purpose of review This will critically highlight the role leukotrienes as mediators renal diseases and drug nephrotoxicity. It also discuss recently identified mechanism cysteinyl induction action, propose clinical implementation these findings. Recent findings Since last reviewed in 1994, were shown to mediate drug-associated nephrotoxicity, transplant rejection morbidity several models diseases. Although may be released by various infiltrating leukocytes, a recent study demonstrated that cytotoxic agents trigger production leukotriene C4 (LTC4) mouse kidney cells activating biosynthetic pathway based on microsomal glutathione-S-transferase 2 (MGST2). LTC4 then elicits nuclear accumulation hydrogen peroxide-generating NADPH oxidase 4, leading oxidative DNA damage cell death. inhibitors, commonly used systemic asthma drugs, alleviated proximal tubular attenuated morbidity. Summary Cysteinyl mast symptoms asthma, including bronchoconstriction vasoconstriction. Therefore, effective inhibitors approved orally administered drugs. The cytotoxicity nephrotoxic are involved numerous diseases, suggest such drugs ameliorate drug-induced well some

参考文章(43)
Antonio Di Gennaro, Jesper Z. Haeggström, The leukotrienes: immune-modulating lipid mediators of disease. Advances in Immunology. ,vol. 116, pp. 51- 92 ,(2012) , 10.1016/B978-0-12-394300-2.00002-8
Ryuichi Mashima, Torayuki Okuyama, The role of lipoxygenases in pathophysiology; new insights and future perspectives Redox biology. ,vol. 6, pp. 297- 310 ,(2015) , 10.1016/J.REDOX.2015.08.006
Magnus Bäck, William S Powell, Sven-Erik Dahlén, Jeffrey M Drazen, Jilly F Evans, Charles N Serhan, Takao Shimizu, Takehiko Yokomizo, G Enrico Rovati, Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. British Journal of Pharmacology. ,vol. 171, pp. 3551- 3574 ,(2014) , 10.1111/BPH.12665
Ahmed E. Khodir, Hamdy A. Ghoneim, Mona Abdel Rahim, Ghada M. Suddek, Montelukast reduces sepsis-induced lung and renal injury in rats. Canadian Journal of Physiology and Pharmacology. ,vol. 92, pp. 839- 847 ,(2014) , 10.1139/CJPP-2014-0191
David Butterly, Robert F. Spurney, Fred Sanfilippo, Sherif Ibrahim, Thomas M. Coffman, Paul E. Klotman, Leukotrienes in renal transplant rejection in rats. Distinct roles for leukotriene B4 and peptidoleukotrienes in the pathogenesis of allograft injury. Journal of Immunology. ,vol. 152, pp. 867- 876 ,(1994)
KENT DOI, YOSHIFUMI HAMASAKI, EISEI NOIRI, KAZUO NOSAKA, TAKAKO SUZUKI, AKIKO TODA, TAKAO SHIMIZU, TOSHIRO FUJITA, AKIHIDE NAKAO, Role of leukotriene B4 in accelerated hyperlipidaemic renal injury Nephrology. ,vol. 16, pp. 304- 309 ,(2011) , 10.1111/J.1440-1797.2010.01387.X
A. Atakan, H. Arikan, B. Macunluoglu, S. Tuglular, G. Ulfer, F. Cakalagaoglu, C. Ozener, E. Akoglu, Renal Protective Effects of Leukotriene Receptor Blockers in an Experimental Model of Cyclosporine Nephrotoxicity Meeting of the Turkish Transplantation Society. ,vol. 40, pp. 279- 284 ,(2008) , 10.1016/J.TRANSPROCEED.2007.11.026
Stephan W. Reinhold, Thomas Scherl, Benjamin Stölcker, Tobias Bergler, Ute Hoffmann, Christian Weingart, Miriam C. Banas, Dmitrij Kollins, Martin C. Kammerl, Bernd Krüger, Bernhard Kaess, Bernhard K. Krämer, Bernhard Banas, Lipoxygenase Products in the Urine Correlate with Renal Function and Body Temperature but not with Acute Transplant Rejection Lipids. ,vol. 48, pp. 167- 175 ,(2013) , 10.1007/S11745-012-3751-5